46 results about "Stapled peptide" patented technology

A method for preparing stapled peptides. The stapled peptides, including helical stapled peptides, are prepared according to a photochemically-based method, a [3+2] cycloaddition reaction. The helical stapled peptides exhibit increased helicity, thermal stability and cell permeability.

The present invention provides stapled polypeptides of the Formulae (I) and (VI): (I) (VI) and salts thereof; wherein the groups =====; R1a, R1b, R1c, R2a, R3a, R2b, R3b, R4a, R4b, RA, RZ, L1a, L1b, L2, L3, XAA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.

Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker, and particles comprising such conjugates have been designed which can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

The present invention relates to a stapled peptide, a preparation method thereof and the use thereof, and more specifically to an amphipathic alpha-helical stapled peptide comprising hydrophobic amino acids and hydrophilic amino acids, a preparation method thereof, and the use thereof for intracellular delivery of an active substance.

The invention relates to stapled peptides for restraining osteoclast differentiation and a preparation method and application of the stapled peptides for restraining osteoclast differentiation. Aminoresins are used as a carrier, according to the amino acid sequence of a formwork FRATtide:Ac-DPHRLLQQLVLSGNLIKEAVRRLHSR-NH2 in a DIC-Oxime condensation system, through an Fmoc solid phase synthesis method, a peptide chain is obtained by synthetizing, based on reserving key amino acid residues, S5 is used for replacing original amino acid in the specific positions, and liner-chain peptides connected to the resin are subjected to olefin metathesis reaction and cyclization in a dichloroethane solution of a Grubbs I reagent, and then are cut down from the resin, so that the target stapled peptidesare obtained. The method disclosed by the invention is simple to realize, and high in production rate, and the stapled peptides are high in purity. Further experiment confirms that the stapled peptides can notably restrain osteoclast differentiation, and have potential application value in treatment of relevant diseases of osteoporosis and the like.

The invention relates to a stapled peptide type compound or pharmaceutically acceptable salt thereof, a magnetic resonance imaging agent and application thereof as well as a magnetic resonance imagingmethod. The stapled peptide type compound has a general formula structure shown in a formula (I), wherein R1, R2, R3, Ln and Xaa are defined in the specification. The stapled peptide type magnetic resonance imaging compound can penetrate a cell membrane, and enter a cell nucleus to be combined with an estrogen receptor located in the cell nucleus, and intracellular imaging is carried out specifically and selectively in a targeting manner. (The formula (I) is described in the specification).

The present invention relates to a Beclin1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds.

The invention discloses novel stapled peptides serving as a KRASG12C / SOS1 inhibitor and application of the novel stapled peptides. Also provided are a composition comprising these stapled peptides anda method for using such peptides in the treatment of cancers. The stapled peptides are more stable in alpha-helical conformation to some extent; the stapled peptides are higher in affinity with KRASG12C protein; the enzymolysis capability of resisting trypsin and alpha-chymotrypsin is better; besides, the plasma stability of the stapled peptides is greatly enhanced, and the stapled peptides are derived from an alpha-helical binding region of SOS1 protein and KRAS protein and inhibit the activation of the KRAS protein. The invention also relates to a preparation method of the novel stapled peptides, a pharmaceutical composition containing these stapled peptides, and application of the stapled peptides independently used or in combination with other compounds for the prevention or treatmentof cancers (such as non-small cell lung cancer).

The invention discloses an olefin thioether stapled peptide. The olefin thioether stapled peptide is characterized in that the structure of the olefin thioether stapled peptide is represented by a formula (I) which is shown in the specification, wherein X is a polypeptide composed of n natural amino acids, n is an integer in the range of 2-4, m1 and m2 are integers in a value range of 1-3, C is analpha-carbon atom in cysteine, and Y1 is a polypeptide composed of 3-8 natural amino acids, and preferably, Y2 is a polypeptide composed of 2-5 natural amino acids or any one of the natural amino acids. The stapled peptide molecules show obvious anti-proliferative activity in different tumor cells, and can be used for treating tumor diseases.

The invention discloses a cationic bridged stapled peptide. The stapled peptide is a cyclic polypeptide with 10-20 amino acid residues, and has the following sequences and structural characteristics:a polypeptide sequence can be shown as a general formula P<n>-K<c>-P<m>-K<c>-P, wherein the P<n>, the P<m> and the P are polypeptide fragments with n, m and i amino acid residues, the n and thei are natural numbers, the m is 3 or 6, the K represents lysine, and the c represents that a cyclic structure is formed between two lysine side chain amino groups. The invention provides a preparationmethod and application of the cationic bridged stapled peptide. A cyclic structure is innovatively formed on one side of the hydrophilic surface of amphiphilic cationic antibacterial peptide, and thestaple antibacterial peptide is prepared. The antibacterial peptide has the following advantages: the antibacterial peptide has broad-spectrum antibacterial activity, and especially has a significantinhibition effect on clinical drug-resistant bacteria; the structure is simple and synthesis is easy; the biological stability is good; the antibacterial peptide can be applied to prevention and treatment of human or animal infectious diseases or tumors.

The present disclosure provides novel polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a stapled peptide comprising a peptide and at least one staple which holds the peptide in an alpha-helical confirmation, and a cyclic cell-penetrating peptide (cCPP) conjugated, directly or indirectly, to the stapled peptide. The present disclosure demonstrates that cCPPs can be usedto confer consistent cell-permeability to stapled peptides.

Presently disclosed is a method of modulating Hepatitis B virus (HBV) replication, by contacting the cell with at least one agent that modulates at least one factor from a specified group consisting of SNAI2, SOX7 and other factors, the screening of said agent and use thereof in a medicament for treating HBV infection or disease or condition associated with a HBV infection in a subject. In one preferred embodiment, the agent is one peptide derived from SOX7 or SNAI2 or stapled peptides thereof. As a separate invention, a method of identifying at least one factor that modulates replication of a virus is also disclosed.

The invention discloses a thioester stapled peptide. The thioester stapled peptide is characterized in that a peptide chain contains segments shown as a formula (I) or a formula (II) in the description, wherein the segments are positioned at end parts or middle parts of the peptide chain. In the formula (I) and the formula (II), each y is separately selected from one of 20 protein amino acids. Theinvention further discloses a method for preparing the thioester stapled peptide. According to the method, DTC (Dithiocarbamates) synthesis reaction is introduced into the preparation of an alpha-helical conformation-locked polypeptide, an dithiocarbamate link arm is formed on a side chain of a peptide segment in order to stabilize the alpha-helical conformation of the polypeptide and fulfill theaim of locking the conformation. According to the polypeptide conformation locking strategy, the problems of product isomerization, poor water solubility, dependence on solid-phase cyclization and the like can be effectively solved.

Cyclized peptides derived from the hyaluronan binding region of RHAMM are provided. Pharmaceutical compositions and methods for using the peptides and pharmaceutical compositions are also provided.

The invention relates to improvements in drug delivery and to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (StaP's) or ii) stitching three or more amino acids to form stitched CPP's (StiP's). More particularly there is provided a drug carrying cell penetrating molecule (DCCPM) comprising: a biologically active compound (BAC), and a cell penetrating agent (CPA), which BAC and CPA are linked directly or via a bi-functional linker (BFL). The CPA is a stabilized peptide(CPP) which has a conformation imposed upon it by stapling to form a stapled peptide (StaP) or stitching to form a stitched peptide (StiP). The StiP or StaP comprise a cross link or bridge between atleast two amino acids of the peptide and the cross link or bridge provides a cyclisation between at least two amino acids which are not formed by an olefin metathesis. Cyclisation may be achieved by one or more of: condensation of an aldehyde or ketone with a hydrazine or protected hydrazine; a thiol-ene Michael addition; a di-sulfide formation; a Huisgen 1, 3 di-polar cycloaddition; a reaction between an amine and carboxylic acid; a singlet or triplet based carbine reaction; or a Suzuki or Sonogashira coupling.

The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.

The present disclosure provides novel polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a stapled peptidyl beta-catenin ligand and at least one staple which holds the peptidyl ligand in an α-helical confirmation, and a cell-penetrating peptide (CPP) conjugated, directly or indirectly, to the stapled peptide.

The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.

The present invention relates to peptidomimetic macrocycles comprising at least one macrocycle-forming linker and an amino acid sequence chosen from the group consisting of: i) an amino acid sequence with at least about 50%, 60%, 70%, 80%, 90%, or 95% sequence identity to a human sequence IRAK2 54-71 (SEQ ID No 1) and 100% identity with the amino acids in the positions 5-6, 9-11, 14-15 or ii) an amino acid sequence with at least about 50%, 60%, 70, 80%, 90%, or 95% sequence identity to a human sequence IRAKM 66-83 (SEQ ID No2) and 100% identity with the amino acids in the positions 5-6, 9-11, 13-14, wherein the peptidomimetic macrocycle comprises an α-helix and at least two natural or two non-natural amino acids crosslinked by a macrocycle-forming linker. It also concerns method of preparation of said peptidomimetic macrocycles and uses thereof, pharmaceutical composition and uses thereof, in particular as inhibitors of inflammatory pathways.

Presently disclosed is a method of modulating Hepatitis B virus (HBV) replication, by contacting the cell with at least one agent that modulates at least one factor from a specified group consisting of SNAI2, SOX7 and other factors, the screening of said agent and use thereof in a medicament for treating HBV infection or disease or condition associated with a HBV infection in a subject. In one preferred embodiment, the agent is one peptide derived from SOX7 or SNAI2 or stapled peptides thereof. As a separate invention, a method of identifying at least one factor that modulates replication of a virus is also disclosed.

The present invention relates to a Beclin 1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin 1 coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds.